Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests (DASI-08-713)

This study has been completed.
Sponsor:
Collaborator:
Astellas Pharma Inc
Information provided by (Responsible Party):
Lawrence Phillips, MD, New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00907855
First received: May 22, 2009
Last updated: November 29, 2011
Last verified: November 2011
  Purpose

Cardiac stress testing with functional nuclear imaging is an invaluable technique in the diagnostic and prognostic evaluation of patients with known or suspected ischemic heart disease. Selection of the appropriate type of nuclear stress test: exercise stress Myocardial Perfusion Imaging (MPI) versus pharmacologic stress MPI is crucial for not only diagnostic accuracy and prognostic evaluation, but also for sound clinical decisions and resource utilization.

The Duke Activity Status Index (DASI) is a 12-item questionnaire that utilized self-reported physical work capacity to estimate peak metabolic equivalents (METs) and has been shown to be a valid measurement of functional capacity. The investigators hypothesized that the DASI may be the screening tool that evaluates functional capacity and guides selection of the optimal stress MPI study.


Condition
Ischemic Heart Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Role of the Duke Activity Status Index in the Selection of the Optimal Type of Stress Myocardial Perfusion Imaging Study in Patients With Known or Suspected Ischemic Heart Disease

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Enrollment: 200
Study Start Date: April 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients referred by their primary physician to the Nuclear Lab at NYU School of Medicine for stress myocardial perfusion imaging testing.

Criteria

Inclusion Criteria:

  • Age > 18

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00907855

Locations
United States, New York
Nuclear Cardiology/Stress Lab, NYU Cardiology Division
New York, New York, United States, 10016
Sponsors and Collaborators
New York University School of Medicine
Astellas Pharma Inc
Investigators
Principal Investigator: Jennifer H. Mieres, MD Division of Cardiology, New York University School of Medicine
Study Director: Lawrence Phillips, MD Division of Cardiology, New York University School of Medicine
  More Information

Publications:
Responsible Party: Lawrence Phillips, MD, Director, Nuclear Cardiology, New York University School of Medicine
ClinicalTrials.gov Identifier: NCT00907855     History of Changes
Other Study ID Numbers: NYU DASI 08-713
Study First Received: May 22, 2009
Last Updated: November 29, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by New York University School of Medicine:
Ischemic Heart Disease
Duke Activity Status Index
Stress Myocardial Perfusion Imaging

Additional relevant MeSH terms:
Coronary Artery Disease
Heart Diseases
Ischemia
Myocardial Ischemia
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Coronary Disease
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on November 20, 2014